

NDA

19-463

S-019

NDA 19-463/S-019

Merck & Co., Inc.
Attention: William G. Roberts, M.D.
Director Regulatory Affairs
Sumneytown Pike
West Point, PA 19486

MAR 18 1998

Dear Dr. Roberts:

Please refer to your supplemental new drug application dated December 18, 1997, received December 22, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Timoptic® in OCUDOSE® (timolol maleate ophthalmic solution).

The supplemental application provides for revisions to the Precautions and Adverse Reactions sections of the package insert.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the final printed labeling submitted on December 18, 1997. Accordingly, the supplemental application is approved effective on the date of this letter.

However, we have the following recommended revisions:

1. The generic name printed at the top of each column of the package insert should be revised so that it is in all lower case letters, as timolol maleate ophthalmic solution.
2. Under HYPERSENSITIVITY in the Adverse Events section, "systemic" should be inserted before "allergic reactions."
3. Under SPECIAL SENSES in the Adverse Events section, there should be a semicolon, rather than a comma, between "choroidal detachment following filtration surgery (see PRECAUTIONS, *General*)" and "tinnitus."
4. In the last paragraph of the Adverse Events section, under Nervous System/Psychiatric, there should be a comma, rather than a semicolon, after "catatonia."

5. In the third paragraph of the Overdosage section, the dosage form, "tablets," should be added to the generic name of BLOCADREN.
6. The third paragraph of the Overdosage section is a sentence beginning "Significant lethality was observed..." This sentence may be deleted.

Should additional information relating to the safety and effectiveness of the drug become available, revision of the labeling may be required.

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the package insert directly to:

Division of Drug Marketing, Advertising and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Should a letter communicating important information about this drug product (i.e., a "Dear Doctor" letter) be issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 19-463/S-019
Page 3

If you have any questions, please contact Joanne M. Holmes, M.B.A., Clinical Reviewer, at (301) 827-2090.

Sincerely,

WAC 3/18/98

Wiley A. Chambers, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic, and
Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

cc:

NDA 19-463

HFD-550/Div. files

HFD-550/Dep Dir/Chambers (with labeling)

HFD-550/MO/Ludwig (with labeling)

HFD-550/Clin Rev/Holmes (with labeling)

HFD-550/Proj Mgr/Gorski (with labeling)

DISTRICT OFFICE

HF-2/Medwatch (with labeling)

HFD-92/DDM-DIAB (with labeling)

HFD-40/DDMAC (with labeling)

HFD-613/OGD (with labeling)

HFD-735/DPE (with labeling)

HFI-20/Press Office (with labeling)

Drafted by: jh/March 2, 1998/19463s19.ap

Initialed by:

final:

APPROVAL (AP)

MAR 18 1998

Clinical Review of NDA 19-463
Labeling Supplement

NDA 19-463/S-019

Submission Date: 12/18/97
Receipt Date: 12/22/97
Review Date: 2/20/98

Applicant: Merck & Co., Inc.
Sumneytown Pike
West Point, PA 19486

**Applicant's
Representative:** William G. Roberts, M.D.
610-397-7052

Drug: Timoptic® 0.25% and 0.5% (timolol maleate ophthalmic solution)
in Ocudose

**Pharmacologic
Category:** Beta adrenergic blocker

Related Review: Medical Officer's Review #2 of NDA 20-869, Cosopt
(dorzolamide hydrochloride and timolol maleate ophthalmic
solution), dated 2/12/98.

Submitted: A Special Supplement-Changes Being Effected containing revised
labeling (as FPL) with additions and revisions to the Precautions
and Adverse Reactions sections. Other changes to the Clinical
Pharmacology, Precautions, Adverse Reactions, Dosage and
Administration, and How Supplied sections were previously made
and approved for S-013 and S-018, approved 5/16/97 and 6/22/97,
respectively, but FPL had not been sent in after the approval
letters. This submission of FPL includes those revisions.

Following is the labeling submitted by the company. Reviewer
recommended deletions are noted by ~~strikeout~~ and additions by
shading within the review.



7950515


**PRESERVATIVE-FREE STERILE
OPHTHALMIC SOLUTION**
in a Sterile Ophthalmic
Unit Dose Dispenser
TIMOPTIC®
0.25% AND 0.5%
(TIMOLOL MALEATE OPTHALMIC SOLUTION)
in **OCUDOSE®**
(DISPENSER)

DESCRIPTION

Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(*tert*-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The nominal optical rotation of timolol maleate is:

$$[\alpha]_{405}^{25} \text{ in } 0.1N \text{ HCl } (C = 5\%) = -12.2^\circ$$

Its molecular formula is $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$ and its structural formula is:



Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.

Timolol maleate ophthalmic solution is supplied in two formulations: Ophthalmic Solution TIMOPTIC* (timolol maleate ophthalmic solution), which contains the preservative benzalkonium chloride; and Ophthalmic Solution TIMOPTIC* (timolol maleate ophthalmic solution), the preservative-free formulation.

Preservative-free Ophthalmic Solution TIMOPTIC is supplied in OCUDOSE*, a unit dose container, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths: Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.25% contains 2.5 mg of timolol (3.4 mg of timolol maleate). Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.5% contains 5.0 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients: monobasic and dibasic sodium phosphate, sodium hydroxide to adjust pH, and water for injection.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta₁ and beta₂ (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Reviewer's comments: *"Mechanism of Action" was added as a subheading for consistency with Timoptic. Acceptable.*

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

TIMOPTIC (timolol maleate ophthalmic solution), when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of TIMOPTIC (timolol maleate ophthalmic solution) can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC (timolol maleate ophthalmic solution) is well maintained.

The precise mechanism of the ocular hypotensive action of TIMOPTIC (timolol maleate ophthalmic solution) is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

Pharmacokinetics

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

Reviewer's comments: *Pharmacokinetics subheading and text added for consistency with Timoptic. Acceptable.*

Clinical Studies

In controlled multiclinic studies in patients with untreated intraocular pressures of 22 mmHg or greater, TIMOPTIC (timolol maleate ophthalmic solution) 0.25 percent or 0.5 percent administered twice a day produced a greater reduction in intraocular pressure than 1, 2, 3, or 4 percent pilocarpine solution administered four times a day or 0.5, 1, or 2 percent epinephrine hydrochloride solution administered twice a day.

Reviewer's comments: *Clinical Studies subheading added for consistency with Timoptic. Acceptable.*

In these studies, TIMOPTIC (timolol maleate ophthalmic solution) was generally well tolerated and produced fewer and less severe side effects than either pilocarpine or epinephrine. A slight reduction of resting heart rate in some patients receiving TIMOPTIC (timolol maleate ophthalmic solution) (mean reduction 2.9 beats/minute standard deviation 10.2) was observed.

INDICATIONS AND USAGE

Preservative-free TIMOPTIC in OCUDOSE is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Preservative-free TIMOPTIC in OCUDOSE may be used when a patient is sensitive to the preservative in TIMOPTIC (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.

CONTRAINDICATIONS

Preservative-free TIMOPTIC in OCUDOSE is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see **WARNINGS**); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see **WARNINGS**); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

WARNINGS

As with many topically applied ophthalmic drugs, this drug is absorbed systemically.

The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate (see CONTRAINDICATIONS).

Cardiac Failure

Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.

In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Preservative-free TIMOPTIC in OCUDOSE should be discontinued.

Obstructive Pulmonary Disease

Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which TIMOPTIC in OCUDOSE is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including Preservative-free TIMOPTIC in OCUDOSE.

Major Surgery

The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

Diabetes Mellitus

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

Thyrotoxicosis

Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

PRECAUTIONS

General

Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with Preservative-free TIMOPTIC in OCUDOSE, alternative therapy should be considered.

Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g. timolol).

Angle-closure glaucoma: In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil. Timolol maleate has little or no effect on the pupil. TIMOPTIC in OCUDOSE should not be used alone in the treatment of angle-closure glaucoma.

Anaphylaxis: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

Muscle Weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

Information for Patients

Patients should be instructed about the use of Preservative-free TIMOPTIC in OCUDOSE.

Since sterility cannot be maintained after the individual unit is opened, patients should be instructed to use the product immediately after opening, and to discard the individual unit and any remaining contents immediately after use.

Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. (See CONTRAINDICATIONS.)

Drug Interactions

Although TIMOPTIC (timolol maleate ophthalmic solution) used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC (timolol maleate ophthalmic solution) and epinephrine has been reported occasionally.

Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Preservative-free TIMOPTIC in OCUDOSE should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

Calcium antagonists: Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Preservative-free TIMOPTIC in OCUDOSE, and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided.

Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

Quinidine: Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6.

Reviewer's comments: *The precaution on quinidine has been added. Supporting literature and Worldwide Experience System (WAES) Reports were provided. Acceptable.*

Injectable Epinephrine: (See PRECAUTIONS, General, Anaphylaxis)

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year oral study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.

In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000 times, respectively, the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.

The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.

Timolol maleate was devoid of mutagenic potential when tested *in vivo* (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and *in vitro* in a neoplastic cell transformation assay (up to 100 µg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 µg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.

Pregnancy-Teratogenic effects:

Pregnancy Category C. Teratogenicity studies with timolol in mice, rats and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

There are no adequate and well-controlled studies in pregnant women. Preservative-free TIMOPTIC in OCUDOSE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from timolol in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

The most frequently reported adverse experiences have been burning and stinging upon instillation (approximately one in eight patients).

Reviewer's comments: *Some adverse events previously listed under oral timolol have now been seen with timolol ophthalmic solution. They have been moved into the appropriate body systems in the paragraphs for timolol ophthalmic solution.*
Adverse events newly reported for timolol ophthalmic solution, and not previously noted for oral timolol, have been added to the appropriate body system in the paragraph on oral timolol.
The changes are acceptable.

The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations:

BODY AS A WHOLE

Headache, asthenia/fatigue, and chest pain.

CARDIOVASCULAR

Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud's phenomenon, and cold hands and feet.

Reviewer's comments: *Edema, claudication, Raynaud's phenomenon, and cold hands and feet were moved from the oral timolol paragraph.*

DIGESTIVE

Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.

IMMUNOLOGIC

Systemic lupus erythematosus.

NERVOUS SYSTEM/PSYCHIATRIC

Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.

Reviewer's comments: *The above subsection was rearranged. Insomnia, nightmares, and memory loss were moved from the oral timolol paragraph.*

SKIN

Alopecia and psoriasiform rash or exacerbation of psoriasis.

HYPERSENSITIVITY

Signs and symptoms of ~~systemic~~ allergic reactions, including angioedema, urticaria, and localized and generalized rash.

Reviewer's comments: *Alopecia and psoriasiform rash or exacerbation of psoriasis were added under Skin. Hypersensitivity is now a distinct paragraph, incorporating what had been under Skin, and adding angioedema.*

RESPIRATORY

Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections.

ENDOCRINE

Masked symptoms of hypoglycemia in diabetic patients (see WARNINGS).

SPECIAL SENSES

Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; choroidal detachment following filtration surgery (see PRECAUTIONS, *General*); and tinnitus.

Reviewer's comments: *Dry eyes and tinnitus were moved from the oral timolol paragraph. The comma after "(see PRECAUTIONS, General)" should be replaced with a semicolon.*

UROGENITAL

Retroperitoneal fibrosis, decreased libido, impotence, and Peyronie's disease.

Reviewer's comments *Decreased libido and Peyronie's disease were moved from the oral timolol paragraph.*

The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta blocking agents, and may be considered potential effects of ophthalmic timolol maleate: *Allergic:* Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; *Body as a Whole:* Extremity pain, decreased exercise tolerance, weight loss; *Cardiovascular:* Worsening of arterial insufficiency, vasodilatation; *Digestive:* Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; *Hematologic:* Nonthrombocytopenic purpura; thrombocytopenic purpura, agranulocytosis; *Endocrine:* Hyperglycemia, hypoglycemia; *Skin:* Pruritus, skin irritation, increased pigmentation, sweating; *Musculoskeletal:* Arthralgia; *Nervous*

System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; *Respiratory:* Rales, bronchial obstruction; *Urogenital:* Urination difficulties.

OVERDOSAGE

There have been reports of inadvertent overdose with Ophthalmic Solution TIMOPTIC (timolol maleate ophthalmic solution) resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see also ADVERSE REACTIONS).

Overdosage has been reported with Tablets BLOCADREN* (timolol maleate tablets). A 30 year old female ingested 650 mg of BLOCADREN (maximum recommended oral daily dose is 60 mg) and experienced second and third degree heart block. She recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate, and borderline first degree heart block.

An *in vitro* hemodialysis study, using ¹⁴C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.

DOSAGE AND ADMINISTRATION

Preservative-free TIMOPTIC in OCUDOSE is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be guaranteed after the individual unit is opened, the remaining contents should be discarded immediately after administration.

Preservative-free TIMOPTIC in OCUDOSE is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Preservative-free TIMOPTIC in OCUDOSE in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) administered twice a day.

Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of 0.5 percent TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. (See PRECAUTIONS, *Drug Interactions, Beta-adrenergic blocking agents.*)

HOW SUPPLIED

Preservative-free Sterile Ophthalmic Solution TIMOPTIC in OCUDOSE is a clear, colorless to light yellow solution.

No. 3542 — Preservative-free TIMOPTIC, 0.25% timolol equivalent, is supplied in OCUDOSE, a clear polyethylene unit dose container. Each individual unit contains 0.3 mL of solution, and is available in a foil laminate overwrapped pouch as follows:

NDC 0006-3542-60; 60 Individual Unit Doses
(6505-01-316-8791, 0.25% 60 Individual Unit Doses).

No. 3543 — Preservative-free TIMOPTIC, 0.5% timolol equivalent, is supplied in OCUDOSE, a clear polyethylene unit dose container. Each individual unit contains 0.3 mL of solution, and is available in a foil laminate overwrapped pouch as follows:

NDC 0006-3543-60; 60 Individual Unit Doses
(6505-01-284-5154, 0.5% 60 Individual Unit Doses).

Storage

Store at room temperature, 15-30°C (59-86°F). Protect from freezing. Protect from light.

Because evaporation can occur through the unprotected polyethylene unit dose container and prolonged exposure to direct light can modify the product, the unit dose container should be kept in the protective foil overwrap and used within one month after the foil package has been opened.

Dist by:

 **MERCK & CO., INC.**
West Point, PA 19486, USA

Filled by: PACO
LAKEWOOD, NJ 08701, USA

Issued August 1997
Printed in USA

Recommendations:

The changes proposed are acceptable, and an approval letter may be issued. Revisions noted in the review are recommendations that may be conveyed in the approval letter. They are not terms of approval. The revisions are as follows:

1. The generic name printed at the top of each column of the package insert should be revised so that it is in all lower case letters, as timolol maleate ophthalmic solution.
2. In the Adverse Events section, under HYPERSENSITIVITY, "systemic" should be inserted before "allergic reactions."
3. In the Adverse Events section, under SPECIAL SENSES, there should be a semicolon, rather than a comma, between "choroidal detachment following filtration surgery (see PRECAUTIONS, *General*)" and "tinnitus."
4. In the last paragraph of the Adverse Events section, under Nervous System/Psychiatric, there should be a comma, rather than a semicolon, after "catatonia."

5. In the second paragraph of the Overdosage section, "tablets" should be added to the generic name of BLOCADREN to indicate the dosage form.
6. The third paragraph of the Overdosage section is a sentence beginning "Significant lethality was observed..." It may be deleted

Joanne M. Holmes

3/18/98

Wiley A. Chambers, M.D.

cc:

NDA 19-463

HFD-550/Div files

HFD-550/Dep Dir/Chambers

HFD-550/MO/Ludwig

HFD-550/Clin/Holmes

HFD-550/PMS/Gorski

HF-2/MedWatch

OK 3/18/98



Food and Drug Administration
Rockville MD 20857

NDA 19-463/S-019

Merck Research Laboratories
P.O. Box 4, BLA-20
West Point, PA 19486-0004

Attention: William G. Roberts, M.D.
Director, Regulatory Affairs

Dear Dr. Roberts:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: TIMOPTIC® in Ocusose (preservative-free sterile ophthalmic solution)

NDA Number: 19-463

Supplement Number: S-019

Date of Supplement: December 18, 1997

Date of Receipt: December 22, 1997

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on February 20, 1998, in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Division of Anti-Inflammatory, Analgesic and
Ophthalmic Drug Products, HFD-550
Attention: Document Control Room
Office of Drug Evaluation V
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

Chin Koerner 12/24/97

Chin Koerner, M.S.
Acting Supervisory Consumer Safety Officer
Division of Anti-Inflammatory, Analgesic and
Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

NDA 19-463/S-019
Page 2

cc:

Original NDA 19-463/S-019
HFD-550/Div. Files
HFD-550/CSO/Gorski, L.

SUPPLEMENT ACKNOWLEDGEMENT

William G. Roberts, M.D.
Director
Regulatory Affairs

These copies are
OFFICIAL FDA COPIES
not desk copies.

Merck & Co., Inc.
P.O. Box 4, BLA-20
West Point PA 19486
Fax 610 397 2516
Tel 610 397 7052

NDA NO. 19463 REF. NO. SR-019


NDA SUPPL FOR Labeling

December 18, 1997

ORIGINAL



Michael Weintraub, M.D., Acting Director
Division of Anti-Inflammatory, Analgesic and
Ophthalmic Drug Products - HFD-550
Office of Drug Evaluation V (CDER)
Food and Drug Administration
9201 Corporate Blvd.
Rockville, Maryland 20850



Dear Dr. Weintraub:

SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED

NDA 18-086: Sterile Ophthalmic Solution TIMOPTIC®
NDA 19-463: Preservative-Free Sterile Ophthalmic Solution TIMOPTIC® in OCUDOSE®
NDA 20-330: Sterile Ophthalmic Gel Forming Solution TIMOPTIC-XE®

Pursuant to Section 505(b) of the Food Drug and Cosmetic Act and in accordance with 21 CFR 314.70 (c) we submit a supplement to NDA 19-463.

As indicated on the attached Form FDA 356h, this supplemental application provides for changes in Item 3 of the approved New Drug Application of Preservative-Free Sterile Ophthalmic Solution TIMOPTIC® in OCUDOSE®. The revisions to the label are described in the Summary of Revisions attached to the cover letter.

Attached as Changes Being Effectuated are the following:

1. Printed package circular #7950515 (Issued August 1997)
2. Annotated circular, illustrating the revisions
3. Supporting literature

The circular has been revised as outlined in the summary of revisions.

The revised labeling will be used in all packaging on or before 3/1/98 and in all product sold or distributed on or before 7/1/98.

A set of the revised OCUDOSE® labels, pouches and cartons will be submitted after they are printed as needed for packaging.

A complete field copy of this supplement has been submitted to the FDA Philadelphia District Office.

86-002
GWSK/L
2-20-98
550


Michael Weintraub, M.D., Acting Director
NDA 18-086: TIMOPTIC®
NDA 19-463: TIMOPTIC® in OCUDOSE®
NDA 20-330: TIMOPTIC-XE®
Page 2

As required by Section 306(k)(1) of the Generic Enforcement Act [21 U.S.C. 335a(k)(1)], we hereby certify that, in connection with this application, Merck & Co., Inc. did not and will not use in any capacity the services of any person debarred under subsections 306(a) or (b) of the Act.

We consider the filing of this supplement to be a confidential matter and request that the Food and Drug Administration not make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Please direct questions or need for additional information to William G. Roberts, M.D. (610/397-7052) or, in my absence, Bonnie J. Goldmann, M.D. (610/397-2383).

Sincerely,



William G. Roberts, M.D.
Director
Regulatory Affairs

Attachments

Federal Express #1
Q/YAR/LAC/LTR/CBE-OPHT-2

Desk copy: Ms. Joanne Holmes, HFD-550, 9201 Corporate Blvd.
Federal Express #1

Desk Copy: Philadelphia District Office, FDA, U.S. Custom House
Room 900, 2nd & Chestnut Streets, Phila., PA 19106-2973
Federal Express # 2

Labeling: Original
NDA No: 19463 No. 12-22-97
Reviewed by: Adelman 2/20/98

NDA 19-463

MAR 18 1998

 **MERCK & CO., INC.**
West Point, PA 19486, USA

APPROVED

7950515

**PRESERVATIVE-FREE STERILE
OPHTHALMIC SOLUTION
in a Sterile Ophthalmic
Unit Dose Dispenser**

TIMOPTIC®

**0.25% AND 0.5%
(TIMOLOL MALEATE OPHTHALMIC
SOLUTION)**


**in OCUDOSE®
(DISPENSER)**

DESCRIPTION

Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(*tert*-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The nominal optical rotation of timolol maleate is:

$[\alpha]_{25}^{25^\circ}$ in 0.1N HCl (C = 5%) = -12.2° .
405 nm

Its molecular formula is $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$ and its structural formula is:



Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.

Timolol maleate ophthalmic solution is supplied in two formulations: Ophthalmic Solution TIMOPTIC® (timolol maleate ophthalmic solution), which contains the preservative benzalkonium chloride; and Ophthalmic Solution TIMOPTIC® (timolol maleate ophthalmic solution), the preservative-free formulation.

Preservative-free Ophthalmic Solution TIMOPTIC is supplied in OCUDOSE®, a unit dose container, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths: Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.25% contains 2.5 mg of timolol (3.4 mg of timolol maleate). Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.5% contains 5.0 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients: monobasic and dibasic sodium phosphate, sodium hydroxide to adjust pH, and water for injection.

CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta₁ and beta₂ (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

*Registered trademark of MERCK & CO., Inc.
COPYRIGHT © MERCK & CO., Inc., 1986, 1995
All rights reserved

**TIMOPTIC® (Timolol Maleate Ophthalmic Solution)
in OCUDOSE® (dispenser)**

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

TIMOPTIC (timolol maleate ophthalmic solution), when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of TIMOPTIC (timolol maleate ophthalmic solution) can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC (timolol maleate ophthalmic solution) is well maintained.

The precise mechanism of the ocular hypotensive action of TIMOPTIC (timolol maleate ophthalmic solution) is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

Pharmacokinetics

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

Clinical Studies

In controlled multiclinic studies in patients with untreated intraocular pressures of 22 mmHg or greater, TIMOPTIC (timolol maleate ophthalmic solution) 0.25 percent or 0.5 percent administered twice a day produced a greater reduction in intraocular pressure than 1, 2, 3, or 4 percent pilocarpine solution administered four times a day or 0.5, 1, or 2 percent epinephrine hydrochloride solution administered twice a day.

In these studies, TIMOPTIC (timolol maleate ophthalmic solution) was generally well tolerated and produced fewer and less severe side effects than either pilocarpine or epinephrine. A slight reduction of resting heart rate in some patients receiving TIMOPTIC (timolol maleate ophthalmic solution) (mean reduction 2.9 beats/minute standard deviation 10.2) was observed.

INDICATIONS AND USAGE

Preservative-free TIMOPTIC in OCUDOSE is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Preservative-free TIMOPTIC in OCUDOSE may be used when a patient is sensitive to the preservative in TIMOPTIC (timolol maleate ophthalmic solution), benzalkonium chlo-

7950515

TIMOPTIC® (Timolol Maleate Ophthalmic Solution) in OCUDOSE® (dispenser)

ride, or when use of a preservative-free topical medication is advisable.

CONTRAINDICATIONS

Preservative-free TIMOPTIC in OCUDOSE is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see WARNINGS); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see WARNINGS); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

WARNINGS

As with many topically applied ophthalmic drugs, this drug is absorbed systemically.

The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate (see CONTRAINDICATIONS).

Cardiac Failure

Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.

In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Preservative-free TIMOPTIC in OCUDOSE should be discontinued.

Obstructive Pulmonary Disease

Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which TIMOPTIC in OCUDOSE is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including Preservative-free TIMOPTIC in OCUDOSE.

Major Surgery

The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

Diabetes Mellitus

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

Thyrotoxicosis

Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed

TIMOPTIC® (Timolol Maleate Ophthalmic Solution) in OCUDOSE® (dispenser)

carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

PRECAUTIONS

General

Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with Preservative-free TIMOPTIC in OCUDOSE, alternative therapy should be considered.

Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g. timolol).

Angle-closure glaucoma: In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil. Timolol maleate has little or no effect on the pupil. TIMOPTIC in OCUDOSE should not be used alone in the treatment of angle-closure glaucoma.

Anaphylaxis: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

Muscle Weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

Information for Patients

Patients should be instructed about the use of Preservative-free TIMOPTIC in OCUDOSE.

Since sterility cannot be maintained after the individual unit is opened, patients should be instructed to use the product immediately after opening, and to discard the individual unit and any remaining contents immediately after use.

Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. (See CONTRAINDICATIONS.)

Drug Interactions

Although TIMOPTIC (timolol maleate ophthalmic solution) used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC (timolol maleate ophthalmic solution) and epinephrine has been reported occasionally.

Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Preservative-free TIMOPTIC in OCUDOSE should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

Calcium antagonists: Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Preservative-free TIMOPTIC in OCUDOSE, and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided.

Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

TIMOPTIC® (Timolol Maleate Ophthalmic Solution) in OCUDOSE® (dispenser)

Digitalis and beta-adrenergic antagonists may precipitate a thyroid storm.

Quinidine: decreased the treatment with dine inhibits the CYP2D6.

Injectable Epinephrine:

Carcinogenesis:

In a two-year study in rats, the incidence of pulmonary adenocarcinoma was increased in rats administered 3 mg/kg/day of timolol maleate. In a lifetime study in female mice, the incidence of mammary adenocarcinoma was increased in mice administered 10 mg/kg/day of timolol maleate.

In a lifetime study in female mice, the incidence of mammary adenocarcinoma was increased in mice administered 10 mg/kg/day of timolol maleate. The increase was associated with an increase in the incidence of mammary adenocarcinoma in female mice administered 10 mg/kg/day of timolol maleate.

The increase was associated with an increase in the incidence of mammary adenocarcinoma in female mice administered 10 mg/kg/day of timolol maleate. The increase was associated with an increase in the incidence of mammary adenocarcinoma in female mice administered 10 mg/kg/day of timolol maleate.

Timolol maleate tested in vivo in a genetic assay (dominant lethal test) showed no increase in the number of dominant lethal mutations.

Reproduction studies in rats and mice have shown no evidence of fetotoxicity.

Pregnancy-Teratology:

Pregnancy C in mice, rats and rats administered 10 mg/kg/day of timolol maleate showed no evidence of fetotoxicity.

Labeling: Original
NDA No: 19463 No. 12-22-97
Reviewed by: Adrian 2/20/98

NDA 19-463

1

7950515

tion)

ata-adrenergic
d storm.

ergic blocking
ents should be
ascular insuffi-
duced cerebral
rapy with Pre-
native therapy

ures has been
s suppressant

angle-closure
nt is to reopen
pupil. Timolol
TIMOPTIC in
treatment of

patients with a
lactic reactions
ve to repeated
nge with such
e to the usual
c reactions.
ade has been
istent with cer-
sis, and gener-
ely to increase
henia gravis or

se of Preserva-

the individual
o use the prod-
the individual
after use.

y of bronchial
disease, sinus
icular block, or
this product.

almic solution)
size, mydriasis
OPTIC (timolol
rine has been

who are receiv-
ed for potential
termic and on
of two topical
needed.

used in the
agents, such as
d oral or intra-
sible atrioven-
lar failure, and
diac function,

ervation of the
s administered
drugs such as
ts and the pro-
ycardia, which
xtension.

**TIMOPTIC® (Timolol Maleate Ophthalmic Solution)
in OCUDOSE® (dispenser)**

Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

Quinidine: Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6.

Injectable Epinephrine: (See PRECAUTIONS, General, Anaphylaxis)

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year oral study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.

In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000 times, respectively, the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.

The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.

Timolol maleate was devoid of mutagenic potential when tested *in vivo* (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and *in vitro* in a neoplastic cell transformation assay (up to 100 µg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 µg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.

Pregnancy-Teratogenic effects:

Pregnancy Category C. Teratogenicity studies with timolol in mice, rats and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossi-

**TIMOPTIC® (Timolol Maleate Ophthalmic Solution)
in OCUDOSE® (dispenser)**

fication was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

There are no adequate and well-controlled studies in pregnant women. Preservative-free TIMOPTIC in OCUDOSE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from timolol in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

The most frequently reported adverse experiences have been burning and stinging upon instillation (approximately one in eight patients).

The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations:

BODY AS A WHOLE

Headache, asthenia/fatigue, and chest pain.

CARDIOVASCULAR

Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud's phenomenon, and cold hands and feet.

DIGESTIVE

Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.

IMMUNOLOGIC

Systemic lupus erythematosus.

NERVOUS SYSTEM/PSYCHIATRIC

Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.

SKIN

Alopecia and psoriasiform rash or exacerbation of psoriasis.

HYPERSENSITIVITY

Signs and symptoms of allergic reactions including angioedema, urticaria, and localized and generalized rash.

RESPIRATORY

Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections.

ENDOCRINE

Masked symptoms of hypoglycemia in diabetic patients (see WARNINGS).

SPECIAL SENSES

Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and

7950515

**TIMOPTIC® (Timolol Maleate Ophthalmic Solution)
in OCUDOSE® (dispenser)**

diplopia; pseudophthalmic; choroidal detachment following filtration surgery (see PRECAUTIONS, *General*, and tinnitus.

UROGENITAL

Retroperitoneal fibrosis, decreased libido, impotence, and Peyronie's disease.

The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta blocking agents, and may be considered potential effects of ophthalmic timolol maleate: *Allergic*: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; *Body as a Whole*: Extremity pain, decreased exercise tolerance, weight loss; *Cardiovascular*: Worsening of arterial insufficiency, vasodilation; *Digestive*: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; *Hematologic*: Nonthrombocytopenic purpura; thrombocytopenic purpura; agranulocytosis; *Endocrine*: Hyperglycemia, hypoglycemia; *Skin*: Pruritus, skin irritation, increased pigmentation, sweating; *Musculoskeletal*: Arthralgia; *Nervous System/Psychiatric*: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; *Respiratory*: Rales, bronchial obstruction; *Urogenital*: Urination difficulties.

OVERDOSAGE

There have been reports of inadvertent overdosage with Ophthalmic Solution TIMOPTIC (timolol maleate ophthalmic solution) resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see also ADVERSE REACTIONS).

Overdosage has been reported with Tablets BLOCADREN® (timolol maleate). A 30 year old female ingested 650 mg of BLOCADREN (maximum recommended oral daily dose is 60 mg) and experienced second and third degree heart block. She recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate, and borderline first degree heart block.

Significant lethality was observed in female rats and female mice after a single dose of 900 and 1190 mg/kg (5310 and 3570 mg/m²) of timolol, respectively.

An *in vitro* hemodialysis study, using ¹⁴C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.

DOSAGE AND ADMINISTRATION

Preservative-free TIMOPTIC in OCUDOSE is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be guaranteed after the individual unit is opened, the remain-

**TIMOPTIC® (Timolol Maleate Ophthalmic Solution)
in OCUDOSE® (dispenser)**

ing contents should be discarded immediately after administration.

Preservative-free TIMOPTIC in OCUDOSE is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Preservative-free TIMOPTIC in OCUDOSE in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) administered twice a day.

Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of 0.5 percent TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. (See PRECAUTIONS, *Drug Interactions*, *Beta-adrenergic blocking agents*.)

HOW SUPPLIED

Preservative-free Sterile Ophthalmic Solution TIMOPTIC in OCUDOSE is a clear, colorless to light yellow solution.

No. 3542 — Preservative-free TIMOPTIC, 0.25% timolol equivalent, is supplied in OCUDOSE, a clear polyethylene unit dose container. Each individual unit contains 0.3 mL of solution, and is available in a foil laminate overwrapped pouch as follows:

NDC 0006-3542-60; 60 Individual Unit Doses
(6505-01-316-8791, 0.25% 60 Individual Unit Doses).

No. 3543 — Preservative-free TIMOPTIC, 0.5% timolol equivalent, is supplied in OCUDOSE, a clear polyethylene unit dose container. Each individual unit contains 0.3 mL of solution, and is available in a foil laminate overwrapped pouch as follows:

NDC 0006-3543-60; 60 Individual Unit Doses
(6505-01-284-5154, 0.5% 60 Individual Unit Doses).

Storage

Store at room temperature, 15-30°C (59-86°F). Protect from freezing. Protect from light.

Because evaporation can occur through the unprotected polyethylene unit dose container and prolonged exposure to direct light can modify the product, the unit dose container should be kept in the protective foil overwrap and used within one month after the foil package has been opened.

Dist. by:
 **MERCK & CO., INC.**, West Point, PA 19486, USA

Filled by: PACO
LAKEWOOD, NJ 08701, USA

Issued August 1997
Printed in USA